Latest news with #AlpenglowBiosciences
Business Wire
06-05-2025
- Business
- Business Wire
New Inverted Light-Sheet Microscopy Platform for Research and Clinical Applications
JENA, Germany & SEATTLE--(BUSINESS WIRE)--ZEISS and Alpenglow Biosciences today announced a new partnership to jointly develop an inverted light-sheet microscope and bioinformatics pipeline tailored specifically for clinical applications. Alpenglow, a pioneering 3D spatial biology company specializing in open-top light-sheet microscopy, data processing, and AI-driven analysis for biopharma and clinical applications, has partnered with ZEISS, a global leader in light-sheet imaging technologies and visualization software – including ZEISS Lattice Lightsheet 7 and arivis software. ZEISS and Alpenglow Biosciences join forces to transform clinical pathology with cutting-edge light sheet microscopy and AI-driven analysis, enhancing patient care through precise treatment recommendations. Share By combining the industry-leading technologies of Alpenglow and ZEISS, the collaboration will enable the broader adoption of 3D pathology across research, translational and clinical applications. As part of the multi-phased collaboration, the companies will develop key applications in: Enhanced 3D pathology workflows (enabling microtome-free, direct digitization of entire tissue samples for improved 3D diagnostics and workflow efficiency), translational research (studying disease biology across 3D volumes enabling detection of immune cell infiltration patterns and characterization of novel biomarkers), drug development (understanding mechanisms of action and optimizing patient selection for clinical trial samples), AI-enabled clinical decision support (predicting treatment response and patient prognosis using AI-driven analysis of rich 3D imaging datasets). "Partnering with ZEISS represents a significant step forward in our mission to revolutionize pathology by extracting and analysing the wealth of information contained in every single cell of a biopsy, rather than relying on just a small fraction of the tissue," said Dr. Nicholas Reder, CEO of Alpenglow Biosciences. "ZEISS's long-standing history of innovation in light-sheet microscopy is the perfect complement to our cutting-edge software and AI capabilities. Together, we will innovate and expand our existing 3D pathology platform that not only advances the needs of biopharma but also transforms clinical practice." 'We are excited to collaborate with Alpenglow and leverage their deep expertise in AI and software development," said Dr. Michael Albiez, Head of ZEISS Research Microscopy Solutions. "This partnership combines Alpenglow's rapidly growing reputation with pharmaceutical companies and clinicians with the leadership of ZEISS in light-sheet microscopy, enabling the creation of powerful, fully integrated workflows for 3D pathology, from sample to analytics.' Dr. Albiez further emphasized, 'At ZEISS, we are committed to driving innovation in imaging solutions that bridge the gap between research and clinical applications. This collaboration with Alpenglow marks a significant milestone in advancing workflows for clinical pathology. Together, we are introducing an integrated solution for analysing entire tissue samples and improving reproducibility to meet the evolving needs of both translational research and clinical settings. This collaboration will enable researchers and clinicians to gain deeper insights into tissue and cellular structures with greater efficiency and precision, ultimately facilitating more personalized and effective treatments." The partnership will create the fastest whole tissue imaging solution by combining exacting engineering and arivis visualization platform from ZEISS with Alpenglow's innovative data processing and AI capabilities. Once imaged, a GPU-accelerated imaging analytics pipeline could allow users to go from tissue to clinically impactful insights at the same time or faster than traditional pathology workflows. The generation of 3D images from entire tissues provides the perfect substrate for AI to make individualized treatment predictions for patients. Ultimately, these innovative technologies will deliver tools that streamline pathology workflows and enable earlier, more accurate clinical decision-making. About ZEISS ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue around 11 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (30 September 2024). For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future. With over 46,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 35 production facilities worldwide (30 September 2024). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG. Further information at ZEISS Research Microscopy Solutions ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA and China. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment. Further information at About Alpenglow Biosciences Alpenglow Biosciences is a 3D spatial biology company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D imaging technology. Their platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and clinical trial enrollment using their patented platform. See what you've been missing at
Business Wire
29-04-2025
- Health
- Business Wire
Featured Talk at SID 2025: Prof. Maria Hordinsky and Alpenglow Biosciences Present Innovations in 3D Imaging for Alopecia and Skin Disease
SEATTLE--(BUSINESS WIRE)--Alpenglow Biosciences is proud to sponsor a featured speaker session and networking lunch at the Society for Investigative Dermatology (SID) 2025 Annual Meeting. Attendees will explore cutting-edge 3D Pathology technologies that are unlocking new insights into skin diseases—including alopecia—and transforming dermatological research and care. Lunch will be provided during the session. Featured Speaker Session Talk Title: Advancing Dermatology: 3D Pathology Innovations and Clinical Applications in Alopecia and other Skin Diseases Date: Thursday, May 8, 2025 Time: 12:45 PM – 1:45 PM Location: Sapphire A/B, Hilton San Diego Bayfront Hotel Clinical Presentation: Maria Hordinsky, MD R.W. Goltz Professor and Vice Chair of Research. Department of Dermatology, University of Minnesota. Professor Hordinsky is internationally recognized for her expertise in hair and scalp disorders. Her research has advanced the understanding of the neuroimmune system's role in alopecia and other inflammatory skin conditions. Technical Presentation: Nick Reder, MD, MPH Founder and CEO, Alpenglow Biosciences Dr. Reder will present how Alpenglow's 3D imaging platform captures full-thickness skin at cellular resolution, enabling non-destructive visualization of nerve structure, immune architecture, and the neuroimmune interface. Alpenglow at SID 2025 Alpenglow's 3D Derm Score™ and 3D spatial imaging technologies will also be featured in three collaborative posters, highlighting advances in the study of alopecia, atopic dermatitis, and Mohs micrographic surgery. Learn More and Connect To view Alpenglow's full SID 2025 program, including poster details, booth information, and to schedule a 1:1 meeting, visit: About Alpenglow Biosciences Alpenglow Biosciences is a venture-backed company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D spatial imaging technology. Their 3D spatial biology platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and patient trial enrollment using their patented platform. Five of the top 10 pharma companies already work with Alpenglow to accelerate development timelines, save costs, gain new insights, and improve therapeutic success. To learn more please visit
Yahoo
08-04-2025
- Health
- Yahoo
Alpenglow Biosciences Announces AACR 2025 Dinner Lecture: "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D"
SEATTLE, April 08, 2025--(BUSINESS WIRE)--Alpenglow Biosciences is pleased to announce its upcoming Dinner Lecture during the American Association for Cancer Research (AACR) Annual Meeting 2025. The event, titled "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D," is scheduled for April 27, 2025, from 6:00 PM to 9:00 PM at Mercat a la Planxa, 638 South Michigan Avenue, Chicago, IL 60605. The evening will feature a keynote address by Dr. Sammy Ferri-Borgogno, B.S., M.S., Ph.D., Assistant Professor in Gynecologic Oncology at MD Anderson Cancer Center where she is studying immune landscapes and signaling in the ovarian tumor microenvironment. Dr. Ferri-Borgogno earned her MSc in Medical Biotechnology from the University of Turin, where she investigated alpha-enolase in pancreatic cancer, and later integrated -omics and immunology in her PhD research. Her postdoctoral work focused on epigenetic regulators in pancreatic cancer and stromal-immune interactions in ovarian cancer. Currently, she employs advanced spatial technologies to identify biomarkers linked to chemoresistance and novel therapeutic targets in ovarian cancer treatment. "I'm honored to have Dr. Ferri-Borgogno join us as our keynote speaker," said Nick Reder, MD, MPH, CEO and Founder of Alpenglow Biosciences. "Her work in spatial biology and cancer research is groundbreaking and aligns perfectly with our mission to advance cancer research through cutting-edge imaging technology. We're thrilled to welcome her for what promises to be an inspiring evening." The Dinner Lecture is complimentary for attendees from pharmaceutical, biotech, and academic institutions. RSVP is required and can be completed through the following link: In addition to the Dinner Lecture, Alpenglow Biosciences will be available for one-on-one meetings during the AACR Annual Meeting 2025. To schedule a slot, please visit: For further information, please contact Steve Pemberton. About Alpenglow Biosciences Alpenglow Biosciences is a venture-backed company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D spatial imaging technology. Their 3D spatial biology platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and patient trial enrollment using their patented platform. Five of the top 10 pharma companies already work with Alpenglow to accelerate development timelines, save costs, gain new insights, and improve therapeutic success. To learn more please visit View source version on Contacts Media Contact:media@
